InvestorsHub Logo
Followers 23
Posts 994
Boards Moderated 0
Alias Born 08/22/2013

Re: None

Friday, 03/07/2014 11:46:20 PM

Friday, March 07, 2014 11:46:20 PM

Post# of 415007
A little reminder for new and old taken from last seeking alpha article.

"There are basically three key areas for Elite to overcome in order to reward their shareholders with massive returns on their investment.

1) "Will the product relieve pain and perform similarly, i.e. is it "bio-equivalent" to the branded product"?
YES!
2) "Will Naltrexone be sequestered"?
YES!
3) "Will it be considered to be abuse-deterrent to drug users compared to regular Oxycontin or even new Oxycontin which may have set the bar for approval"?
"Just based on the science of the product, answer three seems to be clear and this study re-enforces what management obviously believes as does Pfizer for that matter as they pursue their one bead product. The first two questions will be settled soon but since Elite is already a very capable drug manufacturer being led by incredibly experienced industry veterans who are personally invested, and trials are being managed by Camargo a leading expert in the field, the odds are very good."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News